Penumbra INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE

25 Feb 2026

PEN

10-K: Penumbra to be Acquired by Boston Scientific for $14.5B

Penumbra, a leading thrombectomy company, announced its acquisition by Boston Scientific for approximately $14.5 billion, following a year of strong revenue and operational income growth.

NYSE

18 Feb 2025

PEN

Penumbra INC

10-K: Penumbra's 2024 10-K Filing Reveals Strategic Shift Amidst Revenue Growth

Penumbra's 2024 10-K filing highlights a strategic exit from the Immersive Healthcare business alongside a 12.9% revenue increase driven by its thrombectomy product line.

NYSE

22 Feb 2024

PEN

Penumbra INC

10-K: Penumbra Inc. Reports Strong 2023 Results Driven by Thrombectomy Sales Growth

Penumbra Inc. saw a significant revenue increase in 2023, driven by strong performance in its thrombectomy product category and overall growth in international markets.